By Monica Heger

This article has been updated to correct the title of a Myriad official.

Myriad Genetics said that it is moving into the next-generation sequencing space with the development of a suite of diagnostic tests for cancer.

Mark Capone, president of Myriad Genetics Laboratories, outlined the company's strategy on using the technology during a late December conference call hosted by investment bank Jefferies on the evolution of next-gen sequencing in clinical practice.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.